1 / 13

Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs

Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division. Ranbaxy Today. India’s largest pharmaceutical company - amongst top 100 in the world, and 9 th generic player in the world

cdouglas
Download Presentation

Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division

  2. Ranbaxy Today... • India’s largest pharmaceutical company - amongst top 100 in the world, and 9th generic player in the world • Global turnover for 2000 $ 505 million • Branded pharmaceuticals, generics and APIs • 5% market share in India • about 12 % of country’s pharmaceutical exports

  3. Ranbaxy Today... International • Products sold in over 40 countries; manufacturing operations in 6 countries including India • Employs about 7000 people, 17% of non Indian origin • Expanding portfolio of international subsidiaries, joint ventures, affiliates and alliances

  4. Key Global markets Americas USA Brazil Europe UK Germany Western Europe Central Europe Eastern Europe Asia - Pacific India Vietnam China Malaysia Thailand Australia Myanmar New Zealand Africa South Africa Egypt Nigeria

  5. Ranbaxy Today... Research & Development • R&D investment - 18% of Indian Pharmaceutical industry (annually) • Increasing focus on discovery of new molecules

  6. Research & Development • Ranbaxy’s advantage • Low cost, high quality • Highly qualified manpower at very low cost • Innovative approach • Areas of focus • Chemical research • Drug delivery • New molecules

  7. Ranbaxy Laboratories Limited • A responsible international player • Cost effective drug development but at the same time a lot of R&D work • Cost competitive quality manufacturing

  8. Ranbaxy Laboratories Limited Non infringing patent and regulatory framework In order to comply with patent and regulatory constraints not only in API but also in BIO-EQUIVALENT generic products Cost implications

  9. Ranbaxy Laboratories Limited Cost differential at production plant • Not GMP: 50 • GMP: 100 • EU: 200 • USA: 300

  10. Ranbaxy Laboratories Limited • Supports the need to supply inexpensive and quality products to poorer countries • But there must be an equal opportunity to recover cost in other markets

  11. Ranbaxy Laboratories Limited Cost recovery in advanced markets is more and more difficult • Pressure from the Authorities to get the drug bill down • Competition/purchasing groups • Big Pharma tightening product patents • Big Pharma post patent strategy stronger (in EU the “Is/Has Been Marketed” interpretation)

  12. Ranbaxy Laboratories Limited Anti-Aids drugs in Africa: $1 per day per patient • Medium to long term there is a risk that poorer countries will not get access to modern medicines • Neglected diseases will remain neglected, no incentive for R&D • Comparitive pricing with more advanced market • Old products will disappear • PI, etc…

  13. Ranbaxy Laboratories Limited The mission: To become a research based international pharmaceutical company The goal $ 1 billion by 2004 Cecile H Miles Head of Western Europe Division

More Related